When I sit down with leadership teams, the conversation almost always drifts to talent retention, yet a massive blind spot remains completely unaddressed. If one in ten women working through the menopause has left a job because of symptoms, the question for any organisation with a material proportion of senior women is not whether menopause affects retention, but how much of its leadership pipeline is quietly leaking.
The CIPD found in 2023 that 6% of employed women aged 40-60 experiencing menopause transition had already left work because of insufficient support, while 17% had considered leaving. For HR Directors, CFOs and Risk leaders, I treat this strictly as a workforce-risk exposure with measurable consequences rather than a wellbeing initiative competing for discretionary budget: lost institutional knowledge, slower succession, higher replacement costs, weakened client continuity and a widening gender gap precisely at the level where women remain most under-represented. Women hold 29% of C-suite roles, according to McKinsey & Company's 2024 research, so every avoidable senior departure carries a disproportionate strategic cost.
The attrition is visible; the cause is not
Menopause rarely appears in exit interviews as a primary reason for resignation. Symptoms such as sleep disruption, anxiety, low mood, joint pain, hot flushes and difficulties with confidence, stamina and performance can affect people long before an employee decides to leave. NHS England identifies these as common symptoms that can affect people at work, including brain fog, fatigue and anxiety.
That creates an attribution problem that frustrates me when analysing exit data. A senior woman may resign citing a better external opportunity, a desire for flexibility, burnout or a change in personal circumstances, while the underlying trigger may be a workplace that has made a manageable health transition unnecessarily difficult. The Fawcett Society's 2022 research found that one in ten women working through the menopause had left a job because of symptoms, while a further 13% had considered leaving.
The scale of under-reporting matters immensely. Among women who took time off because of menopause symptoms, only 30% told their employer or line manager the real reason; many instead cited anxiety, depression or another physical illness. In other words, absence data will understate the issue, and resignation data will obscure it almost entirely.
Why senior departures cost more
The commercial argument for treating menopause as a talent-risk line item rests on the profile of the employees most likely to be affected. Menopause typically occurs during the years in which women have accumulated deep operational knowledge, client relationships, technical expertise and leadership experience. Losing them is not equivalent to losing a recent hire: it removes scarce capability from the organisation and often creates a vacancy that is expensive and slow to fill.
Yet most organisations cannot quantify this exposure. CIPD's 2022 Resourcing and Talent Planning survey found that 72% of employers did not calculate the cost of labour turnover, and only 17% did. That gap is especially problematic for senior roles, where replacement involves executive search, longer vacancy periods, onboarding, lost productivity and the risk that departing expertise leaves with the individual.
I advise a much more disciplined approach to model the exposure by population segment rather than relying on a single company-wide turnover rate. For each senior female cohort, employers should assess:
- The number of women likely to be in perimenopause or menopause transition.
- Current voluntary attrition, internal mobility and promotion rates for that cohort.
- The cost of external replacement, including recruitment, interim cover, ramp-up time and lost revenue or delivery capacity.
- The cost of avoidable absence, reduced productivity and disengagement before departure.
- The value of retained institutional knowledge and leadership continuity.
This does not require intrusive health data. It requires connecting existing HR, absence, engagement, promotion and exit data in a way that reveals whether women in the relevant age band are leaving earlier, declining promotions or disengaging before they resign.
The UK and Nigeria face different versions of the same risk
In the UK, the policy and legal context is becoming clearer. The UK Government now sets out practical workplace adjustments for employees experiencing menopause, including flexible hours, private rest areas, ergonomic furniture, specialist health advice and control over environmental factors such as temperature and ventilation. Where symptoms amount to a disability under the Equality Act 2010, employers may also be under a legal duty to make reasonable adjustments and avoid discrimination.
In Nigeria, the workforce context differs, but the economic logic is equally compelling. Nigerian research suggests a high prevalence of menopausal symptoms, with one study of 250 postmenopausal women in Osun State reporting a mean age at menopause of 58.7 years and a high symptom burden. Another Nigerian study found an early-menopause prevalence of 22.9% among 253 women studied, with higher prevalence among women living with HIV.
For multinational employers, Nigerian financial-services firms, telecoms businesses, professional-services practices and large public-sector organisations, the issue is therefore not confined to UK compliance. Senior women in Nigeria may be managing symptoms while working in high-pressure environments, with less access to confidential occupational-health support or menopause-specific workplace policy. The absence of a UK-style policy framework does not reduce the commercial exposure; it increases the importance of employer-led intervention.
Support is cheaper than replacement
The central economic case is straightforward: early, confidential support is generally less costly than losing an experienced senior leader. Workplace adjustments are often low-cost and operational rather than clinical, encompassing flexible working, adjusted shift patterns, improved ventilation, access to rest facilities, workload review and protected time for concentration-intensive work. The UK Government specifically identifies these categories of adjustment as practical support measures.
NHS England encourages managers to maintain contact with colleagues absent because of menopause-related symptoms and to use wellbeing conversations to explore reasonable adjustments to working patterns. The point is not to medicalise everyday management, but to ensure that a health transition does not become a performance-management issue, a resignation risk or an unmanaged absence.
The return on intervention comes from three sources. First, it reduces avoidable exits among women who would otherwise leave because support arrived too late. Second, it protects productivity by addressing symptoms before they escalate into prolonged absence or reduced performance. Third, it strengthens the employer's ability to retain and promote women into senior roles, where representation remains structurally thin. McKinsey's 2024 research notes that top-performing companies are more likely than others to track attrition and promotion rates for women and to provide menopause support.
What C-Suite leaders should do
Menopause support becomes a credible talent-risk control when it is designed, measured and owned like any other workforce risk. I insist that five actions sit squarely on the executive agenda:
- Put a number on the exposure by building a cohort-level view of senior women aged roughly 40-60, segmented by function, grade, location and tenure, while tracking voluntary attrition, promotion rates, absence patterns and engagement scores while preserving individual confidentiality.
- Make the cost visible to Finance by estimating the replacement cost of senior departures using role-specific assumptions covering recruitment fees, vacancy cover, lost output, onboarding and time to full productivity, and comparing this with the cost of structured support, manager training and workplace adjustments.
- Equip line managers before the crisis point by training them to hold confidential, non-diagnostic conversations and to offer adjustments early, keeping in mind NHS England's guidance that managers have a central role in supporting colleagues whose symptoms affect work.
- Design support for both markets by aligning policy with government guidance and legal obligations on reasonable adjustments in the UK, and adapting the model to local healthcare access, workplace norms and confidentiality expectations in Nigeria rather than importing a policy that does not reflect employees' lived reality.
- Report it as workforce risk by including menopause-related retention exposure in people-risk reporting alongside succession coverage, critical-role attrition and leadership diversity.
From wellbeing programme to risk control
Menopause is not a niche HR topic, and it is not simply a matter of compassion. It is a predictable workforce transition affecting a population that organisations can least afford to lose: experienced women in the middle and senior stages of their careers.
The organisations that treat menopause attrition as a quantifiable talent-risk line item will make better decisions about where to intervene, how much to invest and which leadership roles are exposed. Those that do not will continue to discover the cost only after a resignation letter has been accepted.
Stop treating this as a secondary HR checkbox and audit your workforce data today to expose where your leadership pipeline is leaking talent.